Amgen Inc. (AMGN)

224.13
NASDAQ : Health Technology
Prev Close 224.81
Day Low/High 222.25 / 226.62
52 Wk Low/High 166.68 / 244.99
Avg Volume 3.44M
Exchange NASDAQ
Shares Outstanding 588.25M
Market Cap 130.83B
EPS 13.00
P/E Ratio 17.60
Div & Yield 6.40 (2.68%)
Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

A Pair of Rare Disease Biotech Concerns Worth a Good Look

A Pair of Rare Disease Biotech Concerns Worth a Good Look

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

3 Autopilot Funds for a High-Yield Portfolio

3 Autopilot Funds for a High-Yield Portfolio

This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend

Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend

In the short run the stock of this biotech giant could bounce as momentum has slowed, but the bigger picture is for further weakness.

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

But is a Teva turnaround still coming after the stock's 70% loss in the past five years?

Real Money Post-Industrial Average Leaves Major Indices in the Dust

Real Money Post-Industrial Average Leaves Major Indices in the Dust

RMPIA outperformed once gain during April.

Fibocall: Early Wednesday Texts

Stalking an Entry in Pioneer Natural Resources Into Earnings

Stalking an Entry in Pioneer Natural Resources Into Earnings

Plus a possible setup in Amgen as earnings approach.

Are These Stocks the Best of the Best?

Are These Stocks the Best of the Best?

Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.

Amgen Rated New Outperform at BMO

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

The Real Money Post Industrial Average Continues to Soar

The Real Money Post Industrial Average Continues to Soar

The RMPIA rose 10.5% during the first half of the current quarter.

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

Real Money Post-Industrial Average Shines in January, Outperforming S&P 500

RMPIA soared 9.9% for the month, led by 11 double-digit gainers.

Apple Jumps After Reporting a Slight Earnings, Revenue Beat

Apple Jumps After Reporting a Slight Earnings, Revenue Beat

Apple shares are up nearly 4% in after-hours trading.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

Amgen Is a Bright Spot in This Stock Market: Here's How to Play It

Amgen Is a Bright Spot in This Stock Market: Here's How to Play It

After the very negative market environment the past few months it is refreshing and exciting to find a stock with some upside potential.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.